Daily Stock Analysis, AST, Asterias Biotherapeutics Inc, priceseries

Asterias Biotherapeutics Inc. Daily Stock Analysis
Stock Information
Open
3.50
Close
3.55
High
3.55
Low
3.35
Previous Close
3.50
Daily Price Gain
0.05
YTD High
5.00
YTD High Date
Jan 25, 2017
YTD Low
3.07
YTD Low Date
Mar 23, 2017
YTD Price Change
-1.00
YTD Gain
-21.98%
52 Week High
5.80
52 Week High Date
Nov 18, 2016
52 Week Low
2.30
52 Week Low Date
Jun 30, 2016
52 Week Price Change
-1.35
52 Week Gain
-27.55%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 5. 2015
3.36
Jan 16. 2015
3.91
9 Trading Days
16.37%
Link
LONG
Feb 26. 2015
3.95
Mar 23. 2015
7.14
17 Trading Days
80.67%
Link
LONG
Apr 7. 2015
7.29
Apr 29. 2015
12.23
16 Trading Days
67.77%
Link
LONG
Aug 27. 2015
3.82
Sep 9. 2015
4.20
8 Trading Days
10.01%
Link
LONG
Feb 26. 2016
3.64
Mar 15. 2016
5.00
12 Trading Days
37.42%
Link
LONG
Sep 7. 2016
3.13
Sep 29. 2016
4.25
16 Trading Days
35.80%
Link
LONG
Nov 9. 2016
3.25
Nov 25. 2016
4.73
11 Trading Days
45.64%
Link
Company Information
Stock Symbol
AST
Exchange
NYSE MKT
Company URL
http://asteriasbiotherapeutics.com
Company Phone
510-456-3805
CEO
Stephen Lahue Cartt
Headquarters
California
Business Address
6300 DUMBARTON CIRCLE, FREMONT, CA 94555
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001572552
About

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine.

Description

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine. The company develops therapeutic products in the areas of neurology and oncology. It is developing AST-VAC1, an autologous product candidate that completed Phase II clinical trialS for the treatment of acute myelogenous leukemia; AST-VAC2, an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase that is in pre-clinical stage; and AST-OPC1, which is in Phase I/IIa clinical trials for the treatment of spinal cord injury, multiple sclerosis, and stroke. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Menlo Park, California. Asterias Biotherapeutics, Inc. is a subsidiary of BioTime, Inc.